Last reviewed · How we verify
Ombrabulin (AVE8062)
Ombrabulin is a vascular disrupting agent that binds to tubulin and disrupts microtubule dynamics, causing selective destruction of tumor vasculature and tumor cell death.
Ombrabulin is a vascular disrupting agent that binds to tubulin and disrupts microtubule dynamics, causing selective destruction of tumor vasculature and tumor cell death. Used for Non-small cell lung cancer (NSCLC), Ovarian cancer, Other solid tumors.
At a glance
| Generic name | Ombrabulin (AVE8062) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Vascular disrupting agent |
| Target | Tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ombrabulin targets the tubulin-microtubule system in endothelial cells of tumor blood vessels, leading to rapid vascular collapse and tumor necrosis. Unlike conventional chemotherapy that primarily targets dividing cancer cells, vascular disrupting agents preferentially affect the abnormal vasculature supporting tumors, causing ischemic necrosis of the tumor core. This mechanism allows it to be effective against a broad range of solid tumors.
Approved indications
- Non-small cell lung cancer (NSCLC)
- Ovarian cancer
- Other solid tumors
Common side effects
- Hypertension
- Fatigue
- Nausea
- Vomiting
- Peripheral neuropathy
Key clinical trials
- Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel (PHASE2)
- A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies (PHASE3)
- Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer (PHASE2)
- A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors (PHASE1)
- Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors (PHASE1)
- Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors (PHASE1)
- Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors (PHASE1)
- Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ombrabulin (AVE8062) CI brief — competitive landscape report
- Ombrabulin (AVE8062) updates RSS · CI watch RSS
- Sanofi portfolio CI